secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0000950170-22-018005
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics cuts 37% workforce, suspends FIN-211 trial after Takeda deal ends
--------------------------------------------------------------------------------

- Reduces workforce by 50 employees (~37% of staff) to cut costs.
- Suspends initiation of Phase 1 trial for FIN-211 (autism candidate).
- Estimates $1.6M in severance and related expenses; charges expected in H2 2022.
- Action follows termination of Takeda IBD collaboration and ongoing strategic review.
- Restructuring substantially complete by Q4 2022; cash runway update to come.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022018005/0000950170-22-018005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022018005/fnch-20220901.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer